Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

rs referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisLocated in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 119,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.us.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

*Known as Votubia® (everolimus) tablets for this patient population in Switzerland. If approved in the EU for this patient population, the trade name will be Votubia.

# Rapamune® (sirolimus) and Torisel® (temsirolimus) are registered trad
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 NxStage Medical, Inc. (Nasdaq: NXTM ... reported first quarter financial results that exceed the top ... for the first quarter of 2015 increased 10 percent ... for the first quarter of 2014. The Company,s revenue ... to $78.5 million.  The increase was driven by outperformance ...
(Date:5/6/2015)... N.J. , May 6, 2015  IGI Laboratories, Inc. ... specialty generic pharmaceutical company, will be presenting today at the ... take place on May 6 th and 7 th ... Jason Grenfell-Gardner , CEO and President ... Laboratories, Inc., will present today, May 6, 2015, at 3:30 p.m. ET. ...
(Date:5/6/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ) ("Juniper" ... three-month period ended March 31, 2015. First quarter financial highlights ... increase of 19% as compared to $7.0 million in ... increased 41% year-over-year, enabled by the return of normalized ... in the fourth quarter of 2014; , Service ...
Breaking Medicine Technology:NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 2NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 3NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 4NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 6NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 7NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 8NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 9NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 10NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 11Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11
... urges psoriasis patients to take control,of their health, help ... A study released,this week showing that people with ... should prompt them to take steps to improve their,overall ... study -- published in the Archives of Dermatology and ...
... Holdings, Inc. (OTC Bulletin Board: LIXT) a developer ... cancer, announced the,closing of a private placement. In ... Stock at a price of $0.65 per share ... acted as placement agent and,received $65,000 in commissions ...
Cached Medicine Technology:Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action 2Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action 3Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement 2Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement 3
(Date:5/6/2015)... May 06, 2015 Aging2.0 ... today announced the latest lineup of speakers and sponsors ... The invitation-only event, scheduled for May 18-19 in San ... executives, consumer technology leaders, investors and more than 50 ... cultivate partnerships and discover new products and services for ...
(Date:5/6/2015)... 06, 2015 Hope For The Warriors® ... Casino Night at the New York Athletic Club on ... Hope For The Warriors®, a national nonprofit dedicated to ... and restoring hope for our service members and our ... to support local and nationwide military families. The Barry ...
(Date:5/6/2015)... Novodiax announced today that they will ... with Ed Begley Jr., airing via Discovery Channel ... , This segment will explore Novodiax, a company ... will learn about Novodiax’s polymer detection system-based Direct ... scenes to investigate how, based on this technology, ...
(Date:5/6/2015)... When it comes to advice concerning health ... respected than those of a physician. It is thus ... more weight than those who received no such trustworthy ... University of Georgia and published in the March edition ... advised by their physicians dropped more pounds, on average, ...
(Date:5/6/2015)... 06, 2015 Healthcare marketing agency ... a silver award in the 2015 Aster Awards for ... and Ellis Medicine’s maternity campaign, respectively. The Aster Awards ... organizations and marketing agencies. , The branding campaign ... line — other/misc. category and hospital 150-200 bed group. ...
Breaking Medicine News(10 mins):Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 2Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 3Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 4Health News:4th Annual Casino Night Draws Support for Military Families in New York City Region 2Health News:Novodiax to Be Featured in Upcoming Episode of Innovations TV Series 2Health News:Diet Doc Unveils New Protocol Around Doctor Advised Weight Loss 2Health News:Diet Doc Unveils New Protocol Around Doctor Advised Weight Loss 3Health News:Smith & Jones Wins in 2015 Aster Awards for Healthcare Marketing 2
... enabled its Contract Sales Management and Outsourced Sales Services capabilities with ... ... Boston, MA (PRWEB) August 31, 2008 -- SCiSOURCE, an international provider ... addition of Joseph P. Connell to its Management Team. This announcement ...
... life of retinal cells that fight age-related macular ... Eating plenty of antioxidant-rich food such as blueberries, ... degeneration, the leading cause of age-related blindness in ... , U.S. researchers found that antioxidants disrupt a ...
... Aflac Incorporated,(NYSE: AFL ) announced today that it ... Tokyo, Japan. Members of Aflac Japan,s management and,its sales ... meeting,agenda follows:, September 7, 2008, 8:00 p.m. ... 2008, 9:00 a.m. - 3:30 p.m. Tokyo time) ...
... Conseco Insurance Company, a life,and health insurance company, ... life insurance product, ConsecoLifeOptions. The policy,provides upside potential ... universal life policy that offers the,opportunity for long-term ... 1%. Clients can customize their coverage levels with ...
... to address the issue, DENVER, Aug. 29 ... Former President Bill Clinton called,for a reinvigorated response ... In praising Presidential nominee Barack Obama, Clinton said,"He ... leadership in,an area in which I am deeply ...
... raises odds for malignancy, study finds , , FRIDAY, Aug. ... World War II atomic bomb blasts in Hiroshima and ... the onset of a form of thyroid cancer, new ... linked to a particular genetic mutation involving the so-called ...
Cached Medicine News:Health News:SCiSOURCE LLC Makes Key Addition to its Management Team 2Health News:Antioxidant-Rich Diet May Protect Against Eye Disease 2Health News:Aflac Incorporated to Webcast Tokyo Analysts Meeting 2Health News:Aflac Incorporated to Webcast Tokyo Analysts Meeting 3Health News:ConsecoLifeOptions Launched by Conseco Insurance Company as New Universal Life Product 2Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 2Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 3Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 2Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 3
... surgeons with brighter, crisper, magnified views of ... many minimally invasive spine procedures. It is ... of contact. The first graphical touchscreen to ... intuitive user guidance similar to that known ...
Micro Dissecting Curette, 5 1/2", Round....
14 cm, very delicate, round cupped jaws, straight jaws, 3.0 mm...
Wilson pituitary forcep, flattened tip, 3 mm bite, 145 mm effective....
Medicine Products: